Joon Lee
Stock Analyst at Truist Securities
(4.66)
# 183
Out of 4,834 analysts
119
Total ratings
56.19%
Success rate
37.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joon Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics | Reiterates: Buy | $95 → $75 | $27.40 | +173.72% | 8 | Apr 28, 2025 | |
| ARVN Arvinas | Maintains: Buy | $65 → $21 | $6.26 | +235.46% | 6 | Apr 9, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $76 → $150 | $73.39 | +104.39% | 8 | Mar 31, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $90 → $50 | $8.08 | +519.20% | 4 | Mar 4, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $175 → $85 | $37.20 | +128.49% | 5 | Mar 3, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $190 → $200 | $107.22 | +86.53% | 5 | Feb 19, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $100 → $120 | $36.31 | +230.49% | 5 | Feb 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $460 → $520 | $434.38 | +19.71% | 3 | Feb 11, 2025 | |
| LRMR Larimar Therapeutics | Initiates: Buy | $18 | $1.87 | +862.57% | 1 | Jan 29, 2025 | |
| ARGX argenx SE | Reiterates: Buy | $660 → $700 | $561.75 | +24.61% | 12 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $44 → $57 | $69.53 | -18.02% | 6 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.59 | +517.76% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $36 | $6.30 | +471.43% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $36 | $23.78 | +51.39% | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $1.40 | +473.48% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $13 → $8 | $6.61 | +21.03% | 11 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $17 | $11.69 | +45.42% | 7 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $118 → $90 | $58.27 | +54.45% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $40 | $2.05 | +1,851.22% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $106.07 | +88.55% | 2 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $2.56 | +95.31% | 7 | Sep 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.28 | +448.78% | 1 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $280 | $2.89 | +9,588.58% | 1 | Oct 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $27 → $34 | $20.40 | +66.67% | 1 | Mar 16, 2021 |
Viking Therapeutics
Apr 28, 2025
Reiterates: Buy
Price Target: $95 → $75
Current: $27.40
Upside: +173.72%
Arvinas
Apr 9, 2025
Maintains: Buy
Price Target: $65 → $21
Current: $6.26
Upside: +235.46%
Corcept Therapeutics
Mar 31, 2025
Maintains: Buy
Price Target: $76 → $150
Current: $73.39
Upside: +104.39%
Intellia Therapeutics
Mar 4, 2025
Maintains: Buy
Price Target: $90 → $50
Current: $8.08
Upside: +519.20%
Praxis Precision Medicines
Mar 3, 2025
Maintains: Buy
Price Target: $175 → $85
Current: $37.20
Upside: +128.49%
Axsome Therapeutics
Feb 19, 2025
Maintains: Buy
Price Target: $190 → $200
Current: $107.22
Upside: +86.53%
CRISPR Therapeutics AG
Feb 12, 2025
Maintains: Buy
Price Target: $100 → $120
Current: $36.31
Upside: +230.49%
Vertex Pharmaceuticals
Feb 11, 2025
Maintains: Buy
Price Target: $460 → $520
Current: $434.38
Upside: +19.71%
Larimar Therapeutics
Jan 29, 2025
Initiates: Buy
Price Target: $18
Current: $1.87
Upside: +862.57%
argenx SE
Jan 14, 2025
Reiterates: Buy
Price Target: $660 → $700
Current: $561.75
Upside: +24.61%
Jan 8, 2025
Reiterates: Buy
Price Target: $44 → $57
Current: $69.53
Upside: -18.02%
Jan 8, 2025
Initiates: Buy
Price Target: $16
Current: $2.59
Upside: +517.76%
Nov 12, 2024
Maintains: Buy
Price Target: $17 → $36
Current: $6.30
Upside: +471.43%
Nov 11, 2024
Maintains: Buy
Price Target: $30 → $36
Current: $23.78
Upside: +51.39%
Nov 5, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $1.40
Upside: +473.48%
Oct 30, 2024
Maintains: Hold
Price Target: $13 → $8
Current: $6.61
Upside: +21.03%
Oct 22, 2024
Maintains: Buy
Price Target: $12 → $17
Current: $11.69
Upside: +45.42%
Sep 17, 2024
Maintains: Buy
Price Target: $118 → $90
Current: $58.27
Upside: +54.45%
Aug 14, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $2.05
Upside: +1,851.22%
Mar 20, 2024
Reiterates: Buy
Price Target: $200
Current: $106.07
Upside: +88.55%
Sep 20, 2023
Maintains: Buy
Price Target: $6 → $5
Current: $2.56
Upside: +95.31%
May 10, 2023
Initiates: Buy
Price Target: $18
Current: $3.28
Upside: +448.78%
Oct 20, 2021
Initiates: Buy
Price Target: $280
Current: $2.89
Upside: +9,588.58%
Mar 16, 2021
Upgrades: Buy
Price Target: $27 → $34
Current: $20.40
Upside: +66.67%